Why does ibogaine affect heart rhythm?

Ibogaine blocks hERG potassium channels — the channels that control rapid cardiac repolarization. Blocking them slows repolarization, which lengthens the QT interval on the EKG. A prolonged QT interval creates conditions under which torsades de pointes can occur. Torsades is a ventricular arrhythmia that can degenerate into ventricular fibrillation. This is the mechanism. It is not theoretical — it is the established pharmacological basis for why EKG before ibogaine ceremony is mandatory, not optional.

What QTc is safe for ibogaine ceremony?

A QTc below 450ms in men and below 470ms in women is the threshold for screening clearance. Above those values, ibogaine's additional QT-prolonging effect creates an unacceptable risk of torsades de pointes. This is not a soft guideline — it is a hard clinical threshold. People above it are not appropriate candidates regardless of their history or motivation. People close to but below the threshold require individual physician assessment.

Can I do ibogaine if I have a heart condition?

It depends on the specific condition. Some cardiac histories are absolute contraindications: QT prolongation above threshold, prior myocardial infarction with ongoing structural damage, active arrhythmias, congenital long QT syndrome. Others — mild controlled hypertension, a prior arrhythmia that has fully resolved — may be compatible with ceremony after physician review. The only way to determine this is through a 12-lead EKG reviewed by a physician during the screening process. A self-assessment or general cardiac clearance from a GP who is not familiar with ibogaine's cardiac pharmacology is not equivalent.

Has anyone died from ibogaine cardiac complications?

Yes. Published case reports and case series of ibogaine-related fatalities consistently identify two patterns: people who had cardiac conditions that would have been identified by pre-ceremony EKG, and people who received ibogaine without continuous monitoring by a physician present on site. The deaths were not random. They were predictable given what the pharmacology does and what monitoring can catch. The safety framework that exists around legitimate ibogaine ceremony is a direct response to this evidence.

Is EKG required every time, or just the first ceremony?

Every ceremony requires a new EKG. Cardiac status changes — QTc can change with age, health conditions, medications, or other factors that develop between ceremonies. The EKG that cleared someone for a first ceremony two years ago tells you nothing about their current cardiac status. Anyone who has started QT-prolonging medications since their last ceremony is not currently a candidate without a new physician review.

What medications prolong QT and interact with ibogaine?

SSRIs (particularly citalopram and escitalopram, which have the most pronounced QT effects), certain antipsychotics (haloperidol, ziprasidone, quetiapine at higher doses), some antibiotics (azithromycin, fluoroquinolones), certain antiemetics (ondansetron), and methadone. This is not an exhaustive list. Complete medication review is part of pre-ceremony screening. Anyone on medications they are unsure about should disclose them during intake — the physician review will assess each one.

Who should not attempt ibogaine ceremony for cardiac reasons?

Anyone with a QTc above 450ms (men) or 470ms (women). Anyone with a recent myocardial infarction. Anyone with active, uncontrolled arrhythmia. Anyone with congenital long QT syndrome. Anyone currently taking QT-prolonging medications without completed supervised discontinuation. Anyone whose cardiovascular status has not been assessed by a physician who understands ibogaine's cardiac pharmacology. These are not risk tolerances — they are disqualifiers.

Does 5-MeO-DMT also carry cardiac risk?

5-MeO-DMT does not carry the same QT prolongation risk as ibogaine — its receptor profile is different, and it does not act on hERG channels in the same way. However, 5-MeO-DMT ceremony still requires medical screening, including cardiac assessment, because the physiological stress of the experience and the individual's baseline health status are relevant regardless of the primary cardiac mechanism. A person with severe structural heart disease is not a candidate for either medicine.

Ibogaine Cardiac Safety: What QT Prolongation Actually Means

Ibogaine blocks specific potassium channels in the heart, delaying cardiac repolarization. That delay—measurable on an EKG as a prolonged QT interval—is the mechanism behind every cardiac fatality ever associated with ibogaine. EKG before ceremony is not precautionary paperwork. It is how conditions that cause those fatalities are identified before they cause them.

This is a research post about what ibogaine does to the heart, why the QT interval is the relevant measurement, and which cardiac conditions make ceremony genuinely dangerous. The disqualifiers here are not preferences. They are physiological facts.

Key facts

Ibogaine blocks hERG potassium channels, prolonging cardiac repolarization
QT prolongation can cause torsades de pointes—a ventricular arrhythmia that can degenerate into ventricular fibrillation
Baseline QTc >450ms (men) or >470ms (women) is an absolute contraindication
A 12-lead EKG reviewed by a physician is required before every ceremony, not as a formality but as the primary cardiac risk screen
An on-site physician for the full 12–24 active hours is required for safe monitoring—not on call, present
The Stanford 2023 study enrolled 30 veterans with cardiologist-reviewed EKG screening before treatment; the 88% average PTSD symptom reduction occurred within that framework
Published ibogaine fatalities have consistently involved either unidentified cardiac conditions or the absence of monitoring

What ibogaine does to the heart

Ibogaine binds to hERG potassium channels—the channels responsible for rapid repolarization of the cardiac action potential. When those channels are partially blocked, repolarization slows. The QT interval on the EKG lengthens. This is not unusual for a drug with ibogaine’s pharmacological complexity; many common medications produce the same effect. What makes ibogaine’s version more consequential is the magnitude: ibogaine produces meaningful QT prolongation at therapeutic doses, not at overdose.

The specific clinical concern is torsades de pointes—a rapid, irregular ventricular arrhythmia whose name describes its appearance on an EKG: a twisting of the points around the isoelectric line. Torsades is not reliably self-terminating. It can degenerate into ventricular fibrillation, which is fatal without immediate defibrillation. That is the clinical chain. It does not happen to everyone whose QT interval is prolonged. It happens to people whose baseline QT is already elevated, who encounter the additional load of ibogaine’s effect, under the physiological stress of a 12–24 hour active experience.

This is why cardiac screening before ibogaine is not precautionary. It is a direct response to a specific, understood pharmacological mechanism. Providers who conduct ibogaine ceremony without it are not taking a calculated risk. They are removing the primary safeguard against an identified failure mode.

Why the QT interval matters more than people expect

A normal QTc—the QT interval corrected for heart rate—is below 440ms in men and below 460ms in women. At these baselines, ibogaine’s effect on QT extends the interval into a range where torsades is possible but unlikely. The risk is not zero, which is why on-site monitoring matters regardless of baseline. But it is manageable.

The risk changes sharply when the baseline QTc is already elevated. A person with a QTc of 470ms before any ibogaine has substantially less margin than someone at 430ms. Ibogaine’s QT-prolonging effect sits on top of whatever prolongation already exists. The combination of an elevated baseline, the drug’s pharmacological effect, and the physiological stress of an extended ceremony—dehydration, exertion, autonomic changes, minimal sleep—compounds the load in ways that each factor alone does not capture.

This is why the specific threshold matters. And why providers who administer an EKG without a physician to interpret it are performing a ritual rather than a screen. The EKG identifies conditions the physician needs to act on. Without interpretation, it identifies nothing.

Electrolytes add another layer. Potassium and magnesium levels directly affect QT duration. Hypokalemia—low blood potassium—prolongs the QT interval independent of ibogaine, and the two effects are additive. People arriving depleted from alcohol use disorder, eating disorders, or prolonged inadequate nutrition may have electrolyte imbalances that need correction before they can be medically cleared. The blood panel that accompanies pre-ceremony screening specifically includes these values.

What the EKG actually screens for

A 12-lead EKG before ibogaine ceremony looks for several things specifically:

Baseline QTc: >450ms in men or >470ms in women is an absolute contraindication
Prior myocardial infarction: visible as Q waves in specific leads; indicates structural cardiac damage
Significant arrhythmias at rest: atrial fibrillation not under controlled management, complex ventricular ectopy, Wolff-Parkinson-White syndrome
Bundle branch blocks: can affect QT interval measurement interpretation and cardiac function
Bradycardia: slow resting heart rate can worsen QT prolongation under certain conditions
Left ventricular hypertrophy patterns: suggest elevated chronic cardiovascular load

A resting 12-lead EKG is the standard. It does not require stress testing or imaging for most participants. It requires a physician to read it. The distinction matters because an EKG administered by a facilitator who prints the result but does not have the training to identify a QTc above threshold, or to recognise subtle ischaemic changes, is not the same as a physician-reviewed screen.

The cost structure of legitimate ibogaine ceremony reflects this. The screening itself, combined with an on-site physician for the full active experience, is the primary driver of why ibogaine ceremony at a programme that does this properly costs $2,000–$5,000 CAD. These are not margins. They are the cost of the professional who reviews the EKG, and the cost of the professional who is present for 12–24 hours if something happens.

Absolute cardiac contraindications

These conditions mean ibogaine ceremony is not appropriate, regardless of the person’s history, readiness, or what other treatments have failed:

QTc >450ms (men) or >470ms (women) on a physician-reviewed baseline EKG
Significant cardiac arrhythmia at rest: atrial fibrillation not under controlled management, complex ventricular ectopy, Wolff-Parkinson-White syndrome
Recent myocardial infarction—within the past 12 months at minimum; structural cardiac damage following MI may extend this indefinitely
Known congenital long QT syndrome
Severe structural heart disease
Active use of QT-prolonging medications without supervised discontinuation—certain antipsychotics, some antibiotics, specific antiemetics, and others

The last point intersects directly with the SSRI question. SSRIs are an absolute contraindication for ibogaine for multiple reasons—serotonin syndrome risk is the more acute concern—but several SSRIs also have clinically significant QT-prolonging effects. The supervised taper requirement is not optional. No case is an exception to it.

Any ibogaine provider who skips cardiac screening is not operating safely. The assertion is not rhetorical. EKG and cardiovascular assessment are how QT prolongation, prior MI, and arrhythmias are identified before ceremony, not during it. Providers who remove this step are not offering a more accessible version of ibogaine treatment. They are offering ibogaine without the safeguard that exists specifically because of what ibogaine does to the heart.

What cardiac monitoring during ceremony involves

Pre-ceremony screening identifies who should not proceed. Monitoring during ceremony is for everyone who does. The two are not interchangeable. A person who passes screening can still encounter an arrhythmia during the active phase of the experience—the combination of physiological stress, the drug’s ongoing cardiac effects, and the duration of the experience creates conditions that screening alone cannot fully anticipate.

Monitoring during ibogaine ceremony in a legitimate programme includes:

Continuous cardiac monitoring throughout the active 12–24 hours—not periodic checks, continuous
Pulse oximetry
Blood pressure monitoring at intervals
A physician present for the full active duration—not on call, not reachable by phone, physically present
Equipment and capacity to respond to a cardiac event on site

The 2023 Stanford study—which documented 88% average reduction in PTSD symptoms and 87% average reduction in depression in 30 special operations veterans at one month post-treatment—used cardiologist-reviewed EKG screening before treatment and physician oversight during it. Published in Nature Medicine in February 2023, the study produced those outcomes within a cardiac safety framework. The outcomes and the monitoring are not separable.

Understanding what the Stanford study actually documented and the conditions under which it was conducted clarifies why the safety infrastructure is not a premium add-on. It is the framework the results were produced within.

The pharmacology of ibogaine’s cardiac effects is well-described in the published literature. A 2001 review published in Cardiovascular Drug Reviews established the hERG channel mechanism that explains ibogaine’s QT prolongation. The scientific basis for the screening requirement has been understood for over two decades. The providers who skip it are not unaware of the mechanism. They are aware of it and have decided that cost or convenience takes precedence.

Who Is Not Right for This

Anyone with the cardiac contraindications listed above is not an appropriate candidate. The compelling personal circumstances do not change the physiology. The length of time they have been struggling does not change the physiology. The fact that other treatments have failed does not change the physiology.

Not everyone who applies has a complete picture of their cardiac status. Some people have never had an EKG. Some people have minor cardiac history they have not thought to disclose. Some people are on medications they do not connect to cardiac function. The pre-ceremony screening process exists to surface these specifics—to find what a person does not know about themselves before ceremony reveals it under less controlled conditions.

The screening conversation that ends in no is one of the most difficult things this work involves. People in crisis who have found a thread of hope do not receive a disqualifying EKG result easily. Saying it clearly, without softening it, is not rejection. It is the only accurate thing to say to someone whose specific cardiac profile makes ibogaine genuinely dangerous for them.

People currently taking QT-prolonging medications require supervised discontinuation before they can be assessed. This includes not just SSRIs but certain antipsychotics and other drugs. The process begins with a conversation during intake, not on ceremony day.

Is This Right for You?

The cardiac safety infrastructure around ibogaine ceremony exists because the pharmacology demands it. It is not a response to legal caution or a differentiator in marketing. It is a direct consequence of what ibogaine does to cardiac conduction—and the consequence of getting it wrong is not correctable after the fact.

If you have cardiac history that concerns you—a prior arrhythmia, a borderline EKG reading, a family history of QT prolongation—state it in your application. The intake process includes a physician review of your specific situation. The outcome of that review—cleared, cleared with conditions, or not a candidate—is the only answer that matters. Applying does not commit you to ceremony. It begins the conversation that produces an accurate assessment.

If you want to understand whether ibogaine or 5-MeO-DMT ceremony is appropriate for your situation, the FAQ is the starting point. If you have already reviewed it and want to begin a formal intake, the application is where that process starts. Every application receives a personal response within 2–3 business days.

Cardiac screening is not what makes ibogaine difficult. It is what makes ibogaine safe enough to attempt at all.